1. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149:1018–22.
2. Criado PR, Avancini J, Santi CG, Medrado AT, Rodrigues CE, de Carvalho JF. Drug reaction with eosinophilia and systemic symptoms (DRESS): a complex interaction of drugs, viruses, and immune system. Isr Med Assoc J. 2012;14:577–82.
3. Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting pd-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383–9.
4. Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746–58.
5. National Cancer Institute. Division of Cancer Treatment & Diagnosis. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. Updated 21 Sep 2020. Accessed 21 Sep 2020. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.